scholarly journals Correlation between Serum Brain-Derived Neurotrophic Factor Level and Depression Severity in Psoriasis Vulgaris Patients

2019 ◽  
Vol 7 (4) ◽  
pp. 583-586 ◽  
Author(s):  
Muhammad Sjahrir ◽  
Irma Damayanti Roesyanto-Mahadi ◽  
Elmeida Effendy
Keyword(s):  
Negative Correlation ◽  
Neurotrophic Factor ◽  
Psoriasis Vulgaris ◽  
Severity Index ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depression Severity ◽  
Bdnf Level ◽  
Cross Sectional ◽  
Serum Bdnf

BACKGROUND: Psoriasis vulgaris is a chronic inflammatory skin disorder that can lead to depression. There is a similarity in neurotrophic substance in the pathogenesis of psoriasis and depression; it’s called brain-derived neurotrophic factor (BDNF). BDNF level imbalance potentially affects the severity of psoriasis and depression. AIM: This study aims to know the correlation between serum BDNF level and depression severity in psoriasis vulgaris patient and also the correlation between serum BDNF level and psoriasis vulgaris severity. METHODS: This is an analytical cross-sectional study that 23 psoriasis vulgaris patients participated. All participants have performed serum BDNF level examination with enzyme-linked immunosorbent assay (ELISA). Depression severity assessed with Beck depression inventory-II (BDI-II) and psoriasis severity assessed with psoriasis area and severity index. Correlation between all variables was analysed with Spearman’s correlation test. RESULTS: Serum BDNF level and depression severity are a strongly negative correlation in psoriasis vulgaris patients (r = -0.667 with significant value p = 0.001). There is a moderate negative correlation between serum BDNF level with psoriasis vulgaris severity (r = -0.595 with significant value p = 0.003). CONCLUSION: In psoriasis vulgaris patients, a low level of serum BDNF may increase depression severity and psoriasis vulgaris severity.

Brain-Derived Neurotrophic Factor Modulates the Effect of Sex on the Descending Pain Modulatory System in Healthy Volunteers

Pain Medicine ◽  
2020 ◽  
Vol 21 (10) ◽  
pp. 2271-2279 ◽  
Author(s):  
Assunta Gasparin ◽  
Maxciel Zortea ◽  
Vinicius Souza dos Santos ◽  
Fabiana Carvalho ◽  
Iraci L S Torres ◽  
...  
Keyword(s):  
Sex Differences ◽  
Healthy Volunteers ◽  
Neurotrophic Factor ◽  
Pain Perception ◽  
Motor Evoked Potential ◽  
Brain Derived Neurotrophic Factor ◽  
Pain Modulation ◽  
Cross Sectional ◽  
Motor Pathway ◽  
Serum Bdnf

Abstract Objectives We investigated sex differences and the influence of brain-derived neurotrophic factor (BDNF) in the descending pain modulatory system (DPMS), as measured by change on the numerical pain scale (NPS; 0–10) during conditioned pain modulation (CPM task; primary outcome) and by function of the corticospinal motor pathway and heat pain thresholds (HPTs; secondary outcomes). Methods This cross-sectional study included healthy volunteers ranging in age from 18 to 45 years (32 male and 24 female). Assessment included serum BDNF, HPT, change on the NPS (0–10) during the CPM task, and motor-evoked potential (MEP) using transcranial magnetic stimulation (TMS). Results The MEP (Mv) amplitude was larger in male participants compared with female participants (mean [SE] = 1.55 [0.34] vs mean [SE] = 1.27 [0.27], respectively, P = 0.001). The mean NPS (0–10) during CPM task changed more substantially for female compared with male participants (mean [SE] = −3.25 [2.01] vs mean [SE] = −2.29 [1.34], respectively, P = 0.040). In addition, a higher serum BDNF (adjusted index for age) was associated with a larger decrease of the NPS during CPM task (P = 0.003), although further regression analyses by sex showed that this was only significant for females (P = 0.010). Conclusions Significant sex differences were identified in DPMS function and corticospinal motor pathway integrity. Nevertheless, BDNF was associated with the function of the DPMS in female but not male participants, indicating that sex and neuroplasticity state are crucial factors for pain perception in healthy subjects.

No association of Brain-derived neurotrophic factor with striatal dopamine transporter availability in healthy subjects

2021 ◽  
Author(s):  
Hyun-Yeol Nam ◽  
Seongho Seo ◽  
Myung Jun Lee ◽  
Keunyoung Kim ◽  
In Joo Kim ◽  
...  
Keyword(s):  
Caudate Nucleus ◽  
Dopamine Transporter ◽  
Neurotrophic Factor ◽  
Healthy Subjects ◽  
Brain Plasticity ◽  
Brain Derived Neurotrophic Factor ◽  
Synaptic Function ◽  
Assay Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Bdnf

Abstract Objective Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in brain plasticity, synaptic function, neuronal survival, learning, and memory formation. We aimed to investigate the association of BDNF with dopamine transporter (DAT) availabilities measured by positron emission tomography (PET) in healthy subjects. Methods Thirty-five healthy, male subjects without brain injury, neuropsychological disorders were included in this study. The emission data were acquired over 90 mins with 50 frames after injection of 18F-FP-CIT using PET. Binding potentials (BPNDs) of ventral striatum (VST), caudate nucleus, putamen were measured with the simplified reference tissue method. The serum BDNF level (pg/mL) was measured through enzyme-linked immunosorbent assay method. Results Thirty-five healthy males with a mean age of 24.4 ± 2.7 years were included in this study. Multiple regression was done to investigate the association between striatal BPNDs from VST, caudate nucleus, putamen and serum BDNF after adjusting for age. None of striatal BPNDs from VST (p=0.8450), caudate nucleus (p=0.4783), and putamen (p=0.7994) were associated with serum BDNF. Conclusion Striatal DAT availabilities measured from PET were not associated with the serum BDNF in healthy subjects.

scholarly journals Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance–Related Motor Symptoms in Patients with Parkinson’s Disease

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 684
Author(s):  
Chen Chih Chung ◽  
Pai Hao Huang ◽  
Lung Chan ◽  
Jia-Hung Chen ◽  
Li-Nien Chien ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurotrophic Factor ◽  
Rating Scale ◽  
Brain Derived Neurotrophic Factor ◽  
Postural Instability ◽  
Gait Disturbance ◽  
Enzyme Linked Immunosorbent Assay ◽  
Motor Symptoms ◽  
Bdnf Level

Brain-derived neurotrophic factor (BDNF) is an essential neurotrophin, responsible for neuronal development, function, and survival. Assessments of peripheral blood BDNF in patients with Parkinson’s disease (PD) previously yielded inconsistent results. Plasma exosomes can carry BDNF, so this study investigated the role of plasma exosomal BDNF level as a biomarker of PD. A total of 114 patients with mild to moderate PD and 42 non-PD controls were recruited, and their clinical presentations were evaluated. Plasma exosomes were isolated with exoEasy Maxi Kits, and enzyme-linked immunosorbent assay was used to assess plasma exosomal BDNF levels. Statistical analysis was performed using SPSS version 19.0, and findings were considered significant at p < 0.05. The analysis revealed no significant differences in plasma exosomal BDNF levels between patients with PD and controls. Patients with PD with low plasma exosomal BDNF levels (in the lowest quartile) exhibited a significant association with daily activity dysfunction but not with cognition/mood or overall motor symptoms as assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS). Investigation of UPDRS part III subitems revealed that low plasma exosomal BDNF level was significantly associated with increased motor severity of postural instability and gait disturbance (PIGD)-associated symptoms (rising from a chair, gait, and postural stability) after adjustment for age and sex. In conclusion, although plasma exosomal BDNF level could not distinguish patients with PD from controls, the association with PIGD symptoms in patients with PD may indicate its potential role as a biomarker. Follow-up studies should investigate the association between plasma exosomal BDNF levels and changes in clinical symptoms.

scholarly journals Perbandingan Kadar Brain – Derived Neurotrophic Factor Pasien Psoriasis Vulgaris Dan Bukan Pasien Psoriasis Vulgaris

2019 ◽  
Vol 45 (1) ◽  
Author(s):  
Muhammad Sjahrir ◽  
Elmeida Effendy ◽  
Irma D Roesyanto
Keyword(s):  
Immunosorbent Assay ◽  
Neurotrophic Factor ◽  
Psoriasis Vulgaris ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay

Psoriasis adalah penyakit inflamasi kronik pada kulit, dengan dugaan kuat akibat pengaruh genetik. Psoriasis memiliki karakteristik berupa gangguan pertumbuhan dan diferensiasi epidermis serta keterlibatan agen biokimiawi, imunologik, kelainan vaskular, dan sistem saraf. Keterlibatan sistem saraf pada psoriasis salah satunya diperankan oleh brain-derived neurotrophic factor (BDNF). BDNF telah dikenal luas berperan pada kondisi stres dan depresi, namun BDNF ternyata juga memilki peran menjaga homeostasis korneosit. Penelitian ini bertujuan untuk mengetahui perbedaan kadar BDNF dalam serum pasien psoriasis vulgaris dibandingkan dengan bukan pasien psoriasis vulgaris.Penelitian ini adalah penelitian analitik dengan desain potong lintang. Sebanyak 20 orang pasien psoriasis vulgaris (kasus) dan 20 orang bukan pasien psoriasis vulgaris (kontrol) ikut serta dalam penelitian ini. Pada seluruh subyek penelitian dilakukan pengambilan darah untuk dilakukan pemeriksaan kadar BDNF dalam serum dengan metode enzyme-linked immunosorbent assay (ELISA). Kadar BDNF serum yang diperoleh kemudian dinilai perbedaannya antara kelompok kasus dan kontrol dengan menggunakan uji-t independen.Hasil penelitian didapatkan kadar BDNF dalam serum pasien psoriasis vulgaris lebih rendah secara bermakna (852,99 ± 172,28 pg/ml) dibandingkan dengan bukan pasien psoriasis vulgaris (1202,37 ± 67,06 pg/ml) dengan  nilai p<0,05. Penelitian ini menyimpulkan bahwa terdapat perbedaan yang bermakna antara kadar BDNF serum pasien dan bukan pasien psoriasis vulgaris.        Kata Kunci: psoriasis vulgaris, brain-derived neurotrophic factor

Serum and Aqueous Humor Levels of Brain-Derived Neurotrophic factor in Patients with Primary Open-Angle Glaucoma and Normal Tension Glaucoma

2021 ◽  
Author(s):  
Yu Wan Cha ◽  
Seong Taeck Kim
Keyword(s):  
Aqueous Humor ◽  
Neurotrophic Factor ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Brain Derived Neurotrophic Factor ◽  
Normal Tension Glaucoma ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Open Angle ◽  
Serum Bdnf

Abstract PurposeThis study designed to compare the levels of brain-derived neurotrophic factor (BDNF) in the serum and aqueous humor (AH) of patients with primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG).MethodsThis prospective, observational study consists of 30 patients with POAG, 30 patients with NTG, and 30 healthy controls. The serum and AH BDNF levels were assessed using an enzyme-linked immunosorbent assay.ResultsBDNF levels in serum and AH were markedly lower in the glaucoma groups (POAG and NTG) than in the control group (p < 0.05). When comparing the NTG and POAG groups, the average serum BDNF level was significantly lower in the NTG group than in the POAG group (p < 0.05). The difference in the mean BDNF levels in AH between the POAG and NTG groups was not statistically significant. (p = 0.538).ConclusionWe confirmed that serum BDNF levels were lower in patients with NTG than in those with POAG. BDNF could be a causative systemic biomarker in NTG.

Effects of acupuncture versus cognitive behavioral therapy on brain-derived neurotrophic factor in cancer survivors with insomnia: an exploratory analysis

2021 ◽  
pp. 096452842199939
Author(s):  
Kevin T Liou ◽  
Sheila N Garland ◽  
Q Susan Li ◽  
Keimya Sadeghi ◽  
Jamie Green ◽  
...  
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Cancer Survivors ◽  
Neurotrophic Factor ◽  
Behavioral Therapy ◽  
Brain Derived Neurotrophic Factor ◽  
Exploratory Analysis ◽  
Cognitive Behavioral ◽  
Enzyme Linked Immunosorbent Assay ◽  
Poor Sleep ◽  
Serum Bdnf

Introduction: Decreased brain-derived neurotrophic factor (BDNF) is associated with poor sleep. This study examined the effects of acupuncture versus cognitive behavioral therapy for insomnia (CBT-I) on serum BDNF and sleep outcomes in cancer survivors with insomnia. Methods: This was an exploratory analysis of a randomized clinical trial (n = 160) comparing acupuncture versus CBT-I for cancer survivors with insomnia. Interventions were delivered over 8 weeks. Outcomes were assessed at baseline and week 8. Serum BDNF was evaluated with enzyme-linked immunosorbent assay (ELISA). Sleep was evaluated with the insomnia severity index and consensus sleep diary. Pearson correlations between BDNF and sleep outcomes were calculated. Data analysis was limited to 87 survivors who provided serum samples. Results: Among 87 survivors, the mean age was 61.9 (SD: 11.4) years, 51.7% were women, and 24.1% were non-White. Mean serum BDNF did not significantly increase in acupuncture (n = 50) or CBT-I (n = 37) groups. When analysis was restricted to patients with low baseline BDNF (i.e. levels below the sample median of 47.1 ng/mL), the acupuncture group (n = 22) demonstrated a significant 7.2 ng/mL increase in mean serum BDNF (P = 0.03), whereas the CBT-I group (n = 21) demonstrated a non-significant 2.9 ng/mL increase (P = 0.28). Serum BDNF was not significantly correlated with sleep outcomes (all P > 0.05). Conclusion: Among cancer survivors with insomnia and low baseline BDNF, acupuncture significantly increased serum BDNF levels; however, the clinical significance of this finding requires further investigation. Trial registration no. NCT02356575 (ClinicalTrials.gov)

scholarly journals P1669PROGNOSTIC IMPORTANCE OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN RENAL TRANSPLANTATION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Agnes Molnar ◽  
Edgar Szkibinszkij ◽  
Lilla Lenart ◽  
Adam Hosszu ◽  
Illes Kovacs ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Ischemia Reperfusion ◽  
Graft Function ◽  
Brain Derived Neurotrophic Factor ◽  
Control Group ◽  
Bdnf Level ◽  
Ischemic Time ◽  
Allele Distribution ◽  
Esrd Patients ◽  
Serum Bdnf

Abstract Background and Aims The prevalence of end-stage renal disease (ESRD) has increased ten times higher in the past twenty years, where renal replacement therapy (dialysis or kidney transplantation (KTx)) is the sole life-saving treatment. KTx is the preferred option as it is associated with improved survival and quality of life as well. Delayed graft function (DGF) is one of the main problems affecting long-term kidney survival. Brain-derived neurotrophic factor (BDNF) signalling pathways play pivotal role in mitigating cerebral ischemia/reperfusion injury (IRI), however the relation of BDNF and IRI in KTx is unknown. The aim of our human clinical study was to explore the relationship between serum BDNF concentration, BDNF gene polymorphism and renal graft function after KTx. Method Study characteristics: We enrolled 59 ESRD patients with average age of 54.8±12 years who received KTx. Proportion of male patients was 57%. Average cold ischemic time was 927±310 min, warm ischemic time was 54.5±39 min. DGF occurred in 5 cases. Baseline triple immunosuppression therapy consisted of tacrolimus, mycophenolate or everolimus, and prednisolone. Until now, 44 patients completed the 2 years follow-up. For a comparable control group, we collected blood samples from 79 healthy volunteers with average age of 53.9±16 years and with male gender proportion of 52%. Serum BDNF, creatinine, blood urea nitrogen, haemoglobin, blood glucose level and thrombocyte numbers were measured before KTx and 1 week, 1-, 3-, 6 months, and 1-, 2 years after transplantation, as well as in controls. GFR was estimated based on the CKD-EPI formula. BDNF Val66Met polymorphism was determined by PCR-RFLP. Results There was no difference in genotype or allele distribution between any of the groups, and no correlation could be observed between serum BDNF and different genotypes either. Serum BDNF level was lower in ESRD patients than healthy controls (p=0.03). There was a weak correlation and marginal significance (p=0.056) between eGFR and serum BDNF level in controls, while in KTx recipients this correlation reached higher significance (p=0.01). Above median BDNF values at 1 month after KTx were predictive for better graft function during the 2 observed years. Conclusion Our preliminary human study proposes that BDNF could be a novel biomarker of posttransplant graft function, however further clinical studies with significantly larger population are definitely needed to confirm these results.

scholarly journals ANXIOUS-DEPRESSIVE SYMPTOMATOLOGY AND BRAIN-DERIVED NEUROTROPHIC FACTOR LEVEL IN PATIENTS WITH TENSION HEADACHE

2017 ◽  
Vol 34 (6) ◽  
pp. 34-39
Author(s):  
K V Tyan ◽  
P P Kalinsky ◽  
A V Rakitova
Keyword(s):  
Blood Serum ◽  
Neurotrophic Factor ◽  
Depressive Symptomatology ◽  
Tension Headache ◽  
Brain Derived Neurotrophic Factor ◽  
Test System ◽  
Serotoninergic System ◽  
Bdnf Level ◽  
Group 2 ◽  
Serum Bdnf

Aim. To study the correlation between the blood serum brain-derived neurotrophic factor (BDNF) level and the manifestation of anxious-depressive symptomatology in patients with tension headache. Materials and methods. The study involved 82 patients with tension headache. The method of immune-enzyme assay with test-system ELISA kit was used to measure the blood serum BDNF concentration. Results. The BDNF level in patients with episodic infrequent and frequent tension headaches was comparable with the group of control. Among patients with chronic tension headache, decrease in BDNF level as compared to group 1, group 2 and the control was revealed. The BDNF level is changed, depending on the duration and intensiveness of tension headache. Conclusions. Chronic tension headache causes exhaustion of not only mediator, but of neurotrophic systems of the brain as well. Blood serum BDNF concentration measured permits to assess activity of cerebral neuroplastic processes and to choose neurotrophic therapy for a more rapid triggering of serotoninergic system and arresting of anxious-depressive syndrome.

Brain-derived neurotrophic factor as a suicide factor in mental disorders

2013 ◽  
Vol 26 (6) ◽  
pp. 356-363 ◽  
Author(s):  
Majda Grah ◽  
Mate Mihanovic ◽  
Nedjeljka Ruljancic ◽  
Branka Restek-Petrovic ◽  
Sven Molnar ◽  
...  
Keyword(s):  
Mental Disorders ◽  
Neurotrophic Factor ◽  
Suicidal Behaviour ◽  
Suicide Attempts ◽  
Brain Plasticity ◽  
Critical Role ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Potential Marker ◽  
Serum Bdnf

ObjectiveBrain-derived neurotrophic factor (BDNF) plays a critical role in brain plasticity processes and serum levels have been demonstrated to be altered in patients with different mental disorder including suicidal behaviour. The objective of this study was to examine the association between serum BDNF levels as a possible peripheral indicator of suicide behaviour in subjects suffering from depression, personality disorders (PDs) and adjustment disorders (ADs) with or without suicide attempt.MethodsThe research included 172 randomly selected individuals suffering from recurrent depressive disorder (RDD; F 33.2), emotionally unstable PD (F 60.3) and AD (F 43.2), with or without attempted suicide according to the criteria of the ICD-10 (International Statistical Classification of Diseases and Related Health Problems 10th Revision) and 60 phenotypically health control subjects. In the group of patients, 73% subjects took some form of psychopharmacotherapy. Serum BDNF levels were measured by enzyme linked immunosorbent assay.ResultsSubjects with PD and AD with suicide attempts had significantly lower serum BDNF levels than those without suicide attempts. In groups of subjects with PD and AD, those taking psychopharmacotherapy had higher serum BDNF levels. In the group of subjects with RDD, there were no differences with respect to suicide attempts or psychopharmacotherapy. Logistical regression analysis was indicated that psychopharmcotherapy and serum BDNF levels statistically correlated with suicide attempts.ConclusionThe lower levels of BDNF in subjects suffering from PD and AD with suicide attempts, suggest that the serum BDNF level is a potential marker of suicidal behaviour, independent of mental disorders.

Sign in / Sign up

Export Citation Format

Share Document